Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma

European Journal of Endocrinology

Volumn 162, Issue 2, 2010, Pages 349-356

  Wortmann, Sebastian ^a   Quinkler, Marcus ^b   Ritter, Christian ^a   Kroiss, Matthias ^a   Johanssen, Sarah ^a   Hahner, Stefanie ^a   Allolio, Bruno ^a   Fassnacht, Martin ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; GEMCITABINE; METYRAPONE; MIFEPRISTONE; MITOTANE; STREPTOZOCIN; SUNITINIB; THALIDOMIDE;

ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BURNING MUCOSA; BURNING SENSATION; CANCER SURVIVAL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DESQUAMATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HEMATURIA; HUMAN; HYPERADRENOCORTICISM; LEUKOPENIA; MALE; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RASH; SALVAGE THERAPY; SIDE EFFECT; SURVIVAL TIME; SWEATING; TREATMENT OUTCOME; VOMITING;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; SALVAGE THERAPY; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT FAILURE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 75149143015     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0804     Document Type: Article

References (37)

1. Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M & Worden FP. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocrine-Related Cancer 2005 12 667-680.
2. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF & Proye C. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World Journal of Surgery 2001 25 891-897.
3. Vassilopoulou-Sellin R & Schultz PN. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 2001 92 1113-1121.
4. Allolio B & Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. Journal of Clinical Endocrinology and Metabolism 2006 91 2027-2037.
5. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna X & Bertherat J. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. Journal of Clinical Endocrinology and Metabolism 2006 91 2650-2655.
6. Assie G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, Leboulleux S, Travagli JP, Dromain C, Bertagna X, Bertherat J, Schlumberger M & Baudin E. Prognostic parameters of metastatic adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2007 92 148-154.
7. Libe R, Fratticci A & Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocrine-Related Cancer 2007 14 13-28.
8. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L & Berruti A. Adjuvant mitotane treatment for adrenocortical carcinoma. New England Journal of Medicine 2007 356 2372-2380.
9. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E & Sturgeon C. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 2008 113 3130-3136.
10. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S & Allolio B. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009 115 243-250.
11. Fassnacht M & Allolio B. Clinical management of adrenocortical carcinoma. Best Practice and Research. Clinical Endocrinology and Metabolism 2009 23 273-289.
12. Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M & Allolio B. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2006 91 4501-4504.
13. Berruti A, Terzolo M, Sperone P, Pia A, Casa SD, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F, Reimondo G, Angeli A & Dogliotti L. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocrine-Related Cancer 2005 12 657-666.
14. Khan TS, Imam H, Juhlin C, Skogseid B, Grondal S, Tibblin S, Wilander E, Oberg K & Eriksson B. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Annals of Oncology 2000 11 1281-1287.
15. Koschker AC, Fassnacht M, Hahner S, Weismann D & Allolio B. Adrenocortical carcinoma - improving patient care by establishing new structures. Experimental and Clinical Endocrinology and Diabetes 2006 114 45-51.
16. Zacharieva S, Atanassova I, Orbetzova M, Nachev E, Kalinov K, Kirilov G, Shigarminova R, Ivanova R & Dashev G. Circulating vascular endothelial growth factor and active renin concentrations and prostaglandin E2 urinary excretion in patients with adrenal tumours. European Journal of Endocrinology 2004 150 345-349.
17. Kirschner LS. Emerging treatment strategies for adrenocortical carcinoma: a new hope. Journal of Clinical Endocrinology 2005 91 14-21.
18. Fassnacht M, Kreissl MC, Weismann D & Allolio B. New targets and therapeutic approaches for endocrine malignancies. Pharmacology & Therapeutics 2009 123 117-141.
19. de Fraipont F, El Atifi M, Gicquel C, Bertagna X, Chambaz EM & Feige JJ. Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. Journal of Clinical Endocrinology and Metabolism 2000 85 4734-4741.
20. Kolomecki K, Stepien H, Bartos M & Kuzdak K. Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours. Endocrine Regulations 2001 35 9-16.
21. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R & Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 2004 350 2335-2342.
22. Ramaswamy B, Elias AD, Kelbick NT, Dodley A, Morrow M, Hauger M, Allen J, Rhoades C, Kendra K, Chen HX, Eckhardt SG & Shapiro CL. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clinical Cancer Research 2006 12 3124-3129.
23. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R & Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine 2006 355 2542-2550.
24. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX & Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New England Journal of Medicine 2003 349 427-434.
25. Montoya M, Brown JW & Fishman LM. Comparative effects of chemotherapeutic agents on the growth and survival of human adrenal carcinoma cells in culture. Hormone and Metabolic Research 2008 40 302-305.
26. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F & Saltz L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/ folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. Journal of Clinical Oncology 2008 26 2006-2012.
27. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F & Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of Clinical Oncology 2008 26 2013-2019.
28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC & Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 2000 92 205-216.
29. Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritter C, Strasburger C, Allolio B & Fassnacht M. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. Journal of Clinical Endocrinology and Metabolism 2008 93 2057-2062.
30. Han JY, Hong EK, Lee SY, Yoon SM, Lee DH & Lee JS. Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer. Journal of Clinical Pathology 2005 58 650-654.
31. Uchida K, Danenberg PV, Danenberg KD & Grem JL. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. BMC Cancer 2008 8 386.
32. Summary of product characteristics of capecitabine (Xeloda(R)) by Roche Registration Limited, UK. 2008.
33. Baudin E, Docao C, Gicquel C, Vassal G, Bachelot A, Penfornis A & Schlumberger M. Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma. Annals of Oncology 2002 13 1806-1809.
34. Khan TS, Sundin A, Juhlin C, Wilander E, Oberg K & Eriksson B. Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer. Medical Oncology 2004 21 167-177.
35. Kalialis LV, Drzewiecki KT, Mohammadi M, Mehlsen AB & Klyver H. Spontaneous regression of metastases from malignant melanoma: a case report. Melanoma Research 2008 18 279-283.
36. Oquinena S, Inarrairaegui M, Vila JJ, Alegre F, Zozaya JM & Sangro B. Spontaneous regression of hepatocellular carcinoma: three case reports and a categorized review of the literature. Digestive Diseases and Sciences 2009 54 1147-1153.
37. Abdelrazeq AS. Spontaneous regression of colorectal cancer: a review of cases from 1900 to 2005. International Journal of Colorectal Disease 2007 22 727-736.